Immunosuppressive therapy is effective against IgA nephropathy, but is not always suitable because of serious adverse effects. Magistroni et al. retrospectively reviewed 237 IgA nephropathy cases ...
IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 67 , 504–513 (2005). Article CAS PubMed Google Scholar ...
Immunoglobulin A (IgA) nephropathy, aka Berger disease, is a rare autoimmune disease that affects your kidneys. Though rare, IgA nephropathy (IgAN) is one of the leading causes of kidney failure.
IgA nephropathy is the most common primary glomerulonephritis and contributes to kidney failure. Growing evidence exists that the overactivation of the lectin pathway contributes to the pathogenesis ...
The global IgA Nephropathy Disease Treatment Market is at the forefront of addressing the growing burden of renal diseases worldwide. With a projected value surpassing USD 485 million by 2028, the ...
Doncaster and Bassetlaw Teaching Hospitals (DBTH) has become the first site in Europe to enrol patients in a revolutionary clinical study evaluating the efficacy and safety of Ravulizumab, a potential ...
Renalys Pharma’s sparsentan receives Japanese Orphan Drug Designation for primary IgA nephropathy: Tokyo, Japan Tuesday, December 3, 2024, 11:00 Hrs [IST] Renalys Pharma, Inc., ...